- Home
- EXOD vs VIR Comparison
EXOD vs VIR Comparison
Compare EXOD & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXOD
- VIR
- Stock Information
- Founded
- EXOD 2015
- VIR 2016
- Country
- EXOD United States
- VIR United States
- Employees
- EXOD N/A
- VIR N/A
- Industry
- EXOD
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- EXOD
- VIR Health Care
- Exchange
- EXOD NYSE
- VIR Nasdaq
- Market Cap
- EXOD 944.6M
- VIR 844.9M
- IPO Year
- EXOD N/A
- VIR 2019
- Fundamental
- Price
- EXOD $29.51
- VIR $5.13
- Analyst Decision
- EXOD Strong Buy
- VIR Strong Buy
- Analyst Count
- EXOD 3
- VIR 7
- Target Price
- EXOD $64.33
- VIR $32.86
- AVG Volume (30 Days)
- EXOD 145.7K
- VIR 1.1M
- Earning Date
- EXOD 08-12-2025
- VIR 07-31-2025
- Dividend Yield
- EXOD N/A
- VIR N/A
- EPS Growth
- EXOD N/A
- VIR N/A
- EPS
- EXOD 1.44
- VIR N/A
- Revenue
- EXOD $123,208,000.00
- VIR $20,861,000.00
- Revenue This Year
- EXOD $32.58
- VIR N/A
- Revenue Next Year
- EXOD $27.75
- VIR N/A
- P/E Ratio
- EXOD $19.80
- VIR N/A
- Revenue Growth
- EXOD 71.36
- VIR N/A
- 52 Week Low
- EXOD $12.02
- VIR $4.32
- 52 Week High
- EXOD $117.40
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- EXOD N/A
- VIR 48.62
- Support Level
- EXOD N/A
- VIR $5.00
- Resistance Level
- EXOD N/A
- VIR $5.35
- Average True Range (ATR)
- EXOD 0.00
- VIR 0.24
- MACD
- EXOD 0.00
- VIR 0.02
- Stochastic Oscillator
- EXOD 0.00
- VIR 31.21
About EXOD EXODUS MOVEMENT INC
Exodus Movement Inc is a self-custodial platform that connects people with the world of decentralized finance and the power of the blockchain. Available for desktop and mobile, it allows users to secure, manage and exchange cryptocurrencies like Bitcoin, Ethereum. Geographical presence in Europe, United States, the Middle East, and Africa (EMEA); Asia-Pacific (APAC); and Canada and Latin America (Other Americas).
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.